Do BRAF inhibitors select for populations with different disease progression kinetics?

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Ascierto, Paolo Antonio ^a   Simeone, Ester ^a   Grimaldi, Antonio Maria ^a   Curvietto, Marcello ^a   Esposito, Assunta ^a   Palmieri, Giuseppe ^b   Mozzillo, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Unit of Cancer Genetics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; IPILIMUMAB; VEMURAFENIB;

BRAIN METASTASIS; CANCER GROWTH; CANCER RESISTANCE; DEATH; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; METASTATIC MELANOMA; NOTE; OVERALL SURVIVAL;

ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84874708193     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-61     Document Type: Note

References (9)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
2. Ascierto PA, Chiarion Sileni V, Del Vecchio M, Altomonte M, De Galitiis F, Ridolfi L, Cognetti F, Testori A, Bernengo MG, Queirolo P. The European ipilimumab expanded access programme (EAP): efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma [abstract]. Ann Oncol 2012, 23:ix367.
3. Clinical Trial Result Information An open-label multicenter study on the efficacy of continuous oral dosing of RO5185426 on tumour response in previously treated patients with metastatic melanoma http://www.rochetrials.com/studyResultGet.action?studyResultNumber=NP22657, Clinical Trial Result Information.
4. Clinical Trial Result Information BRIM 3: a randomized, open-label, controlled, multicenter, global study on progression-free and overall survival in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF mutation receiving RO5185426 or dacarbazine http://www.roche-trials.com/studyResultGet.action?studyResultNumber=NO25026, Clinical Trial Result Information.
5. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012, 10:107. 10.1186/1479-5876-10-107, 3464706, 22640478.
6. Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib [abstract]. J Clin Oncol 2012, 30:8569.
7. Fisher R, Ali Z, Edmonds K, Turajlic S, Gore M, Larkin J. Clinical behaviour of metastatic melanoma after progression on vemurafenib [abstract]. Pigment Cell Melanoma Res 2012, 25:856.
8. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 2013, 14:e60-e69. 10.1016/S1470-2045(12)70539-9, 23369684.
9. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010, 8:38. 10.1186/1479-5876-8-38, 2873374, 20406483.